On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA). HG381 for
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15. Please visit our virtual booth for more information on our oncology and preclinical
Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
Thank you for your business, support and partnership in 2020! Medicilon appreciates working with you and hope that the coming year will bring you happiness
